Patents Represented by Attorney, Agent or Law Firm Karen Mangasarian
  • Sulfonamide inhibitors of aspartyl protease
    Patent number: 6720335
    Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
    Type: Grant
    Filed: March 8, 2002
    Date of Patent: April 13, 2004
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Roger D. Tung, Mark A. Murcko, Govinda Rao Bhisetti
  • Mutations of the C-terminal portion of TGF-&bgr; superfamily proteins
    Patent number: 6677432
    Abstract: The invention provides modified proteins and DNAs of the TGF-&bgr; superfamily including modified morphogenic proteins. The proteins of the present invention display altered biological or biochemical attributes. Specifically, the modified proteins are designed through substitutions of amino acids in the finger 2 sub-domain or exchanges of all or part of the finger 2 sub-domain of one TGF-&bgr; superfamily member with the finger 2 sub-domain of another TGF-&bgr; superfamily member.
    Type: Grant
    Filed: August 16, 1999
    Date of Patent: January 13, 2004
    Assignee: Stryker Corporation
    Inventors: Hermann Oppermann, Mei-Sheng Tai, John McCartney
  • Matrix-free osteogenic devices, implants and methods of use thereof
    Patent number: 6426332
    Abstract: Provided herein are methods for inducing bone formation in a mammal sufficient to fill a defect defining a void, wherein osteogenic protein is provided alone or dispersed in a biocompatible non-rigid, amorphous carrier having no defined surfaces. The methods and devices provide injectable formulations for filling critical size defects, as well as for accelerating the rate and enhancing the quality of bone formation in non-critical size defects.
    Type: Grant
    Filed: June 22, 2001
    Date of Patent: July 30, 2002
    Assignee: Stryker Corporation
    Inventors: David C. Rueger, Marjorie M. Tucker
  • Sulfonamide inhibitors of aspartyl protease
    Patent number: 6392046
    Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
    Type: Grant
    Filed: September 30, 1999
    Date of Patent: May 21, 2002
    Assignee: Vertex Pharmaceuticals, Inc.
    Inventors: Roger D. Tung, Mark A. Murcko, Govinda Rao Bhisetti
  • Methods and compositions for identifying morphogenic protein analogs using morphogenic protein responsive inhibitory elements
    Patent number: 6368787
    Abstract: The present invention relates generally to methods and compositions for identifying morphogenic protein analogs. In one embodiment, this invention relates to an osteogenic protein reponsive transcription inhibitory element. This invention also relates to the identified morphogenic protein analogs which can mimic the biological effects of morphogenic proteins, particularly those relating to the BMP family such as osteogenic protein (OP-1), on the regulation of gene expression and tissue inductive capabilities.
    Type: Grant
    Filed: December 16, 1999
    Date of Patent: April 9, 2002
    Assignee: Stryker Corporation
    Inventors: Lee-Chuan C. Yeh, John C. Lee
  • Matrix-free osteogenic devices, implants and methods of use thereof
    Patent number: 6281195
    Abstract: Provided herein are methods for inducing bone formation in a mammal sufficient to fill a defect defining a void, wherein osteogenic protein is provided alone or dispersed in a biocompatible non-rigid, amorphous carrier having no defined surfaces. The methods and devices provide injectable formulations for filling critical size defects, as well as for accelerating the rate and enhancing the quality of bone formation in non-critical size defects.
    Type: Grant
    Filed: February 5, 1998
    Date of Patent: August 28, 2001
    Assignee: Stryker Corporation
    Inventors: David C. Rueger, Marjorie M. Tucker